Standardisation of Study Protocols – Pros and Cons
- 7 September 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 10 (suppl 2), S553-S559
- https://doi.org/10.1093/ecco-jcc/jjw001
Abstract
Designing clinical trials in inflammatory bowel diseases is challenging. Composite scores that have been used for drug approval until recently such as the Crohn’s disease activity index (CDAI) and the Mayo score for ulcerative colitis have been criticized by regulatory bodies for its lack of validation, poor correlation with objective mucosal disease and absence of ‘patient reported outcomes’. Most drug development programs use the ‘classic ‘separation’ between an induction and a maintenance phase. Challenging issues are the ‘ideal timing’ of the primary endpoint for induction and maintenance studies, strategies to reduce placebo response rates and rules for corticosteroids withdrawal. Discussion about which patients to re-randomize after induction into the maintenance phase of the study is critical. Presently, new instruments for disease assessment in IBD are being developed and validated. Central (independent) review of endoscopic recordings at screening and at the end of the intervention will probably become standard. Finally, the most optimal trial design for every individual intervention is likely to depend on the mechanism of action of the medication under study.This publication has 32 references indexed in Scilit:
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2013
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative ColitisGastroenterology, 2011
- Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)Gut, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2010
- An analysis of the placebo effect in Crohn’s disease over timeAlimentary Pharmacology & Therapeutics, 2009
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2005
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980
- Treatment of Ulcerative Colitis with Local Hydrocortisone Hemisuccinate SodiumBMJ, 1958